Efficacy

Skyrizi (Risankizumab) Efficacy in Psoriasis

Skyrizi, which contains the active ingredient risankizumab, is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Clinical trials have demonstrated that Skyrizi is highly effective in achieving clear or almost clear skin. In pivotal phase 3 studies, such as the UltIMMa-1 and UltIMMa-2 trials, a significant proportion of patients treated with Skyrizi achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) score, which is considered a robust measure of efficacy in psoriasis treatment.

The long-term efficacy of Skyrizi has also been evaluated, showing sustained skin clearance over time. The majority of patients who responded to Skyrizi during the initial 16 weeks of treatment maintained their PASI 90 response through one year, with continued treatment every 12 weeks. This sustained response is crucial for patients with psoriasis, as it is a chronic condition that requires long-term management.

Zoryve (Roflumilast) Efficacy in Psoriasis

Zoryve, with the active ingredient roflumilast, is a phosphodiesterase-4 (PDE4) inhibitor. While it is not yet approved by the FDA for the treatment of psoriasis, roflumilast has been studied for its potential off-label use in this condition. In clinical trials, topical formulations of roflumilast have shown promise in reducing the symptoms of plaque psoriasis. The efficacy of roflumilast cream has been evaluated in phase 2 and phase 3 clinical trials, where it has demonstrated significant improvements in PASI scores compared to placebo.

Moreover, roflumilast has been found to be well-tolerated with a favorable safety profile in clinical studies, which is an important consideration for the long-term management of a chronic condition like psoriasis. The potential of Zoryve as a treatment for psoriasis lies in its anti-inflammatory properties, targeting an enzyme involved in the inflammatory pathway that contributes to the pathogenesis of psoriasis. Further research and clinical trials are needed to fully establish the efficacy and safety of roflumilast for psoriasis, and to potentially support its approval for this indication.